Research programme: agammaglobulinaemia-tyrosine-kinase inhibitors - Advinus Therapeutics

Drug Profile

Research programme: agammaglobulinaemia-tyrosine-kinase inhibitors - Advinus Therapeutics

Alternative Names: Bruton's tyrosine kinase inhibitors - Advinus; BTK inhibitors - Advinus Therapeutics

Latest Information Update: 02 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advinus Therapeutics
  • Class Anti-inflammatories; Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Cancer; Inflammation

Highest Development Phases

  • Research Autoimmune disorders; Cancer; Inflammation

Most Recent Events

  • 21 Jan 2016 BTK inhibitors - Advinus Therapeutics is available for licensing as of 21 Jan 2016. www.advinus.com
  • 21 Jan 2016 Early research in Autoimmune disorders in India (unspecified route)
  • 21 Jan 2016 Early research in Cancer in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top